In treatment-resistant depression, two studies found that COMP360 psilocybin therapy reduced depression and one study reported that using precision medicine for ketamine dosing might decrease the high efficacy-low effectiveness gap.

Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment and the majority are mild or moderate in severity.

Data on more than 200,000 individuals revealed that non-SSRI antidepressants were associated with a two-fold increased risk of coronary heart disease, cardiovascular mortality, and all-cause mortality at ten years. There was also evidence that SSRIs were associated with lower rates of hypertension and diabetes.

In the confirmatory trial, Clarity AD, of 1,795 patients with early AD, findings showed a reduction of dementia scoring of 27% vs. placebo. These findings were seen as early as 6 months.

Folic acid (B9) prescription in a population of more than 800,000 individuals, yielded a suicide event rate of 4.73 per 100 000 person-months, compared with a rate of 10.61 per 100 000 person-months without folic acid.

In reverse order of popularity: 10. PECARN Pediatric Head Injury/Trauma Algorithm9. GAD-7 (General Anxiety Disorder-7)8. Ideal Body Weight and Adjusted Body Weight7. Steroid Conversion Calculator6. Calcium Correction for Hypoalbuminemia5. MELD Score (Model For End-Stage Liver Disease) (12 and older)4. Mean Arterial Pressure (MAP)3. CHA₂DS₂-VASc Score for Atrial Fibrillation Stroke Risk2. PHQ-9 (Patient Health Questionnaire-9)1. Creatinine Clearance (Cockcroft-Gault Equation)